Propella Therapeutics is a biopharmaceutical company that has developed a platform that combines lymphatic targeting with a medicinal chemistry optimization process to create best- or first-in-class oncology drugs starting from active moieties that have validated MOAs and biological targets but suffer efficacy limitations due to low bioavailability and / or safety concerns due to overexposure to non-target tissues. Lymphatic targeting enables therapies to be delivered directly to therapeutic target tissues, thereby bypassing plasma compartment safety and efficacy limitations and first-pass liver effects. This approach provides increased bioavailability to tissues of interest including lymph nodes and bone metastatic sites, increased pharmacological activity, reduced liver effects, and an improved therapeutic index. Propella is currently in the Phase 1 portion of a Phase 1/2a study of its lead product candidate, PRL-02, for the treatment of metastatic prostate cancer. The privately held development-stage company, based in Pittsboro, N.C., is dedicated to meeting the needs of cancer patients currently underserved by existing standards of care.
